Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | DNM2 | P50570 | 7/20 | 0.49 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1562316 | 1.00 | KMT2A (0.77) | KMT2ALMNADNM2KCNH3NR1I2 | |
| SCHEMBL17563553 | 1.00 | KMT2A (0.77) | KMT2ALMNADNM2KCNH3NR1I2 | |
| SCHEMBL2238412 | 1.00 | KMT2A (0.77) | KMT2ALMNADNM2KCNH3NR1I2 | |
| SCHEMBL10912439 | 1.00 | KMT2A (0.77) | KMT2ALMNADNM2KCNH3NR1I2 | |
| SCHEMBL7937257 | 1.00 | KMT2A (0.77) | KMT2ALMNADNM2KCNH3NR1I2 | |
| SCHEMBL616128 | 0.98 | KMT2A (0.74) | KMT2ALMNADNM2KCNH3NR1I2 | |
| SCHEMBL7862893 | 0.96 | KMT2A (0.83) | KMT2ALMNADNM2KCNH3NR1I2 | |
| SCHEMBL11787843 | 0.96 | KMT2A (0.83) | KMT2ALMNADNM2KCNH3NR1I2 | |
| SCHEMBL20694824 | 0.94 | KMT2A (0.81) | KMT2ALMNADNM2KCNH3NR1I2 | |
| SCHEMBL7100653 | 0.94 | KMT2A (0.80) | KMT2ALMNADNM2KCNH3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999101-B2 | Genetic material complexing and internalizing capacity; low cytotoxicity; such as 2-[4-(3-amino-propylamino)-6-tetradecylamino-[1,3,5]triazin-2-ylamino]-ethanethiol or its disulphide dimer | POLITECNICO DI MILANO (IT) | 2011-08-16 | — | — | US | disclosed |
| US-7999101-B2 | Genetic material complexing and internalizing capacity; low cytotoxicity; such as 2-[4-(3-amino-propylamino)-6-tetradecylamino-[1,3,5]triazin-2-ylamino]-ethanethiol or its disulphide dimer | POLITECNICO DI MILANO (IT) | 2011-08-16 | — | — | US | disclosed |
| US-7999101-B2 | Genetic material complexing and internalizing capacity; low cytotoxicity; such as 2-[4-(3-amino-propylamino)-6-tetradecylamino-[1,3,5]triazin-2-ylamino]-ethanethiol or its disulphide dimer | POLITECNICO DI MILANO (IT) | 2011-08-16 | — | — | US | disclosed |
| US-20080146518-A1 | Cationic Lipids for the Transfection of Nucleic Acids | POLITECNICO DI MILANO (IL) | 2008-06-19 | — | — | US | disclosed |
| US-20080146518-A1 | Cationic Lipids for the Transfection of Nucleic Acids | POLITECNICO DI MILANO (IL) | 2008-06-19 | — | — | US | disclosed |
| US-20080146518-A1 | Cationic Lipids for the Transfection of Nucleic Acids | POLITECNICO DI MILANO (IL) | 2008-06-19 | — | — | US | disclosed |
| EP-1846378-A2 | CATIONIC LIPIDS FOR THE TRANSFECTION OF NUCLEIC ACIDS | Politecnico Di Milano (IT) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006087752-A2 | CATIONIC LIPIDS FOR THE TRANSFECTION OF NUCLEIC ACIDS | POLITECNICO DI MILANO (IT) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146518-A1 | Cationic Lipids for the Transfection of Nucleic Acids | AARS1, HARS1, LPAR3 | KMT2A 826/4885LMNA 803/4885DNM2 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.